Alnylam Pharmaceuticals
ALNY
#649
Rank
NZ$52.63 B
Marketcap
$408.06
Share price
-7.14%
Change (1 day)
44.14%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$6.55

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$7.00. In 2022 the company made an earnings per share (EPS) of -$15.83 a decrease over its 2021 EPS that were of -$12.27.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$6.55-58.6%
2022-$15.8329.03%
2021-$12.27-3.36%
2020-$12.69-8.48%
2019-$13.877.67%
2018-$12.8839.74%
2017-$9.2212.94%
2016-$8.1638.84%
2015-$5.88-32.88%
2014-$8.76259.44%
2013-$2.44-31.25%
2012-$3.5452.94%
2011-$2.3230.77%
2010-$1.77-8.77%
2009-$1.9478.13%
2008-$1.09-70.78%
2007-$3.7399.09%
2006-$1.87-43.88%
2005-$3.34-82.33%
2004-$18.90-59.23%
2003-$46.36

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.90-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$63.65-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$13.34 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.46-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.88-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.37-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$5.42-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$3.41-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel